1,721,921 research outputs found
Associazione tra livelli sierici di lipoproteina(a) e polimorfismo dimensionale dell'apolipoproteina(a) e danno degli organi bersaglio nell'ipertensione arteriosa.
No full textMechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity
No full textSeveral lines of evidence suggest that insulin resistance and the resultant hyperinsulinaemia are causally related to hypertension. Insulin actions are initiated by binding to a high-affinity transmembrane protein receptor which is present in all mammalian cells. These effects are predominant in skeletal muscle, liver, and fat and involve a number of tissue-specific and biochemically diverse events. Less well known are effects of insulin occurring in tissues not usually considered as insulin targets, which are hypothetical contributors to the pro-hypertensive action of the hormone. These effects include activation of renal sodium reabsorption, stimulation of the sympathetic nervous system, growth-promoting activity on vascular smooth muscle cells, and modulation of transmembrane cation transport Epidemiological investigations have implicated sodium intake in the pathogenesis of hypertension. Because of the sodium-retaining effects of insulin, it has been postulated that insulin resistance with associated hyperinsulinaemia may be critical for the pathogenesis of salt-sensitivity in essential hypertensive subjects. Insulin resistance is present also in strains of rats with genetic hypertension that can be utilized as models to study the molecular mechanisms of this abnormality. In the present article, we summarize the current knowledge of the mechanisms of insulin resistance in rat models of arterial hypertension in which decreased sensitivity to insulin occurs and propose a rationale hypothesis that links insulin resistance with salt-sensitivity and hypertension, J Hypertens 1999, 17:1229-1237 (C) Lippincott Williams & Wilkins
OLMESARTAN MEDOXIMIL ED IDROCLOROTIAZIDE AD ALTO DOSAGGIO PER IL TRATTAMENTO DELL'IPERTENSIONE
No full text
Management of cardiovascular risk in diabetic patients: evolution or revolution?
No full textDiabetes is associated with a marked increase in the risk of cardiovascular disease. Epidemiological evidence shows that hyperglycemia, hypertension and disorders of both lipid and thrombosis are involved in the etiology of cardiovascular disease in diabetes. Intervention trials on each of such factors have demonstrated a favourable effect in terms of reduction of cardiovascular disease, suggesting that even in diabetic patients in whom blood glucose levels are adequately controlled, other cardiovascular risk factors, such as hyperlipidemia, hypertension and prothrombotic state, should be aggressively treated. The need for an aggressive treatment has been recently underscored by the UKPDS (United Kingdom Prospective Diabetes Study) researchers who suggest that "polypharmacy" is now needed for the prevention of diabetic complications, implying that this approach requires an adequate control of all cardiovascular risk factors even using associations of drugs for each of them. A thorough application of these concepts might appear difficult in particular when the resource cost is considered. However, it has been shown that blood glucose, blood pressure and serum lipid control are advantageous in diabetic patients not only in terms of cost/benefit ratio but also in terms of quality of life. In the present article, we will briefly review this evidence and discuss the ethical and socioeconomic concerns that may subsequently ris
INFLUENCE OF ANGIOTENSIN CONVERTING-ENZYME INHIBITION ON THE PROEDEMATOUS ACTIVITY OF NICARDIPINE
No full textUse of isolated peptide belonging to Mycobacterium avium paratuberculosis, having specific homology, or isolated antibody, as biomarker in an in vitro test for diagnosing individual who is susceptible to or who is developing type I diabetes
No full textAbstract: NOVELTY - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, a peptide selected from at least one isolated peptide belonging to Mycobacterium avium paratuberculosis-3865c (MAP3865c), at least one peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to human zinc transporter 8 (ZnT8) sequence after optimal alignment, or at least one isolated antibody specific for the peptide, is used.
USE - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes; and in vaccine for the treatment or prophylaxis of type I diabetes (claimed).
ADVANTAGE - The method is more sensitive than the prior art method; and is able to allow to intervene in time with a treatment for preventing or delaying the onset of type I diabetes, for instance by avoiding, controlling or monitoring Mycobacterium avium paratuberculosis.
DETAILED DESCRIPTION - As biomarker in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, a peptide selected from at least one isolated peptide belonging to Mycobacterium avium paratuberculosis-3865c (MAP3865c), at least one peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to human ZnT8 sequence after optimal alignment, or at least one isolated antibody specific for the peptide; or a peptide selected from at least one isolated peptide belonging to ZnT8 sequence having amino acids 174-194, peptide having an homology of at least 50% in comparison to a corresponding peptide belonging to MAP3865c from amino acids 121-141, or isolated antibodies specific for the peptide, as biomarkers in an in vitro test for diagnosing an individual who is susceptible to or who is developing type I diabetes, is used. INDEPENDENT CLAIMS are included for the following: 1) new isolated nucleic acid molecule encoding for the peptide; 2) new vector comprising the nucleic acid molecule; new isolated cell comprising the vector; 3) a kit comprising a container containing the peptide or the nucleic acid molecule; 4) new isolated antibody specific for the peptide; 5) use of vaccine comprising the isolated peptide for the treatment or prophylaxis of type I diabetes; and 6) use of anti Mycobacterium avium paratuberculosis drugs in the prevention and treatment of type I diabetes
- …
